32.62SEK-3.20%Mkt Cap: 3.25B SEKP/E: —Last update: 2026-06-01
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap3.25B SEK
Enterprise Value3.90B SEK
Revenue (TTM)190.49M SEK
Gross Profit138.71M SEK
Net Income (TTM)-534.11M SEK
Revenue/Share2.124 SEK
Last Price32.62 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees122
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0002148817
Valuation
P/E (Trailing)—
P/E (Forward)-4.57
PEG—
EV/EBITDA-6.86
EV/Revenue20.45
P/S17.64
P/B-12.46
EPS (TTM)-7.94
EPS (Forward)-7.37
52W Range
22.8249% of range42.98
52W High42.98 SEK
52W Low22.82 SEK
Profitability
Gross Margin62.41%
Oper. Margin-411.08%
EBITDA Margin-298.07%
Profit Margin-240.30%
ROE600.18%
ROA-45.78%
Growth
Revenue Growth-47.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-549.17M SEK
CapEx (TTM)—
FCF Margin-182.76%
FCF Yield-10.70%
Net Debt465.80M SEK
Net Debt/EBITDA-0.82
Balance Sheet
Debt/Equity-10.55
Current Ratio3.63
Quick Ratio3.60
Book Value/Sh-2.7050 SEK
Cash/Share6.647 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)75.71 SEK
Target Range35.00 SEK – 103.00 SEK
# Analysts7
Ownership
Shares Out.99.73M
Float64.40M
Insiders9.80%
Institutions47.57%
Technical
SMA 5030.05 (+8.6%)
SMA 20032.30 (+1.0%)
Beta1.50
S&P 52W Chg27.70%
Avg Vol (30d)598.24K
Avg Vol (10d)840.71K
Technical Indicators
RSI (14)60.2
MACD1.4222
MACD Signal1.0183
MACD Hist.+0.4038
BB Upper36.65 SEK
BB Middle30.93 SEK
BB Lower25.22 SEK
BB Width36.95%
ATR (14)2.050 SEK
Vol Ratio (20d)0.60x